Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the randomized phase I/II ADVANTAGE trial (phase II part)
Cetuximab; Cilengitide; Integrin inhibitor; Phase I II; Platinum based chemotherapy with 5 fluorouracil; Recurrent and or metastatic squamous cell carcinoma of the head and neck (R M SCCHN)
ADULT;
AGED;
ANOREXIA;
ARTICLE;
ASTHENIA;
CONTINUOUS INFUSION;
DISEASE COURSE;
DRUG SAFETY;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
FEMALE;
HEAD AND NECK SQUAMOUS CELL CARCINOMA;
HUMAN;
MAINTENANCE THERAPY;
MAJOR CLINICAL STUDY;
MALE;
METASTASIS POTENTIAL;
MULTIPLE CYCLE TREATMENT;
NAUSEA;
OPEN STUDY;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEIN EXPRESSION;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TREATMENT RESPONSE;
TUMOR RECURRENCE;
CETUXIMAB;
CILENGITIDE;
INTEGRIN INHIBITOR;
PHASE I/II;
PLATINUM-BASED CHEMOTHERAPY WITH 5-FLUOROURACIL;
RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M-SCCHN);
Quality of life of patients receiving platinumbased chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck
Mesía R, Rivera F, Kawecki A et al. Quality of life of patients receiving platinumbased chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21: 1967-1973.
Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
Perri F, Longo F, Ionna F et al. Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck. OncoTargets Ther 2009; 2: 243-250.
Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation
Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate. Design, synthesis and clinical evaluation. Anticancer Agents Med Chem 2010; 10: 753-768.
Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas
Fabricius EM, Wildner GP, Kruse-Boitschenko U et al. Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Ther Med 2011; 2: 9-19.
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
Vermorken JB, Guigay J, Mesia R et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 2011; 104: 1691-1696.
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
Reardon DA, Fink KL, Mikkelsen T et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26: 5610-5617.
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 2712-2718.
A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)
Nabors LB, Mikkelsen T, Hegi ME et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012; 118: 5601-5607.
Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III EXTREME trial
(abstract 1018O)
Psyrri A, Licitra L, De Blas B et al. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the phase III EXTREME trial. Ann Oncol 2012; 23 (Suppl 9): ix334-ix335 (abstract 1018O).
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamouscell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
doi: 10.1016/S1470-2045(13)70181-5
Vermorken JB, Stöhlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamouscell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; doi:10.1016/S1470-2045(13)70181-5.
Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review
Isayeva T, Li Y, Maswahu D et al. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol 2012; 6 (Suppl 1): S104-S120.
